Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD)
and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple …

Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of …

Background Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed
CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory …

The achievement of complete response (CR) after high-dose therapy/autologous stem cell
transplantation (HDT/ASCT) is a surrogate for prolonged survival in multiple myeloma; …

We assessed the prognostic value of minimal residual disease (MRD) detection in multiple
myeloma (MM) patients using a sequencing-based platform in bone marrow samples from …

PURPOSE Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2: 1
structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I …

There is limited information on the characteristics, prognostic factors, and outcomes of patients
with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series …

Background Bortezomib plus melphalan and prednisone (VMP) is significantly better than
melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin’s lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

Purpose Complete response (CR) is considered an important goal in most hematologic
malignancies. However, in multiple myeloma (MM), there is no consensus regarding whether …